Collaborative [ENAV] vs Sagimet Biosciences [SGMT] Detailed Stock Comparison
Collaborative
NYSE
Loading...
Sagimet Biosciences
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 17 vital metrics comparison: Collaborative wins in 5 metrics, Sagimet Biosciences wins in 6 metrics, with 0 ties. Sagimet Biosciences appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Collaborative | Sagimet Biosciences | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 14.87 | -5.03 | Sagimet Biosciences |
| Price-to-Book Ratio | 65.85 | 1.80 | Sagimet Biosciences |
| Debt-to-Equity Ratio | -0.02 | 0.12 | Collaborative |
| PEG Ratio | N/A | -0.18 | N/A |
| EV/EBITDA | 1.77 | -2.05 | Sagimet Biosciences |
| Profit Margin (TTM) | 99.92% | 0.00% | Collaborative |
| Operating Margin (TTM) | N/A | 0.00% | N/A |
| Return on Equity | 6.86% | -37.89% | Collaborative |
| Return on Assets (TTM) | -33.17% | -25.61% | Sagimet Biosciences |
| Free Cash Flow (TTM) | N/A | $-42.44M | N/A |
| 1-Year Return | 12.42% | 78.24% | Sagimet Biosciences |
| Price-to-Sales Ratio (TTM) | 0.00 | N/A | N/A |
| Enterprise Value | $-76.38M | $111.83M | Sagimet Biosciences |
| EV/Revenue Ratio | -30.55 | N/A | N/A |
| Revenue per Share (TTM) | $0 | $0 | Collaborative |
| Earnings per Share (Diluted) | $-0.27 | $-1.86 | Collaborative |
| Beta (Stock Volatility) | N/A | 3.27 | N/A |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Collaborative vs Sagimet Biosciences Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Collaborative | 0.09% | 0.67% | 3.71% | 6.29% | 20.14% | 14.77% |
| Sagimet Biosciences | 1.82% | -0.68% | -0.68% | -11.64% | 221.15% | 62.36% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Collaborative | 12.42% | 826.74% | 1,763.44% | 1,091.07% | 2,650.79% | 2,650.79% |
| Sagimet Biosciences | 78.24% | -54.27% | -54.27% | -54.27% | -54.27% | -54.27% |
Performance & Financial Health Analysis: Collaborative vs Sagimet Biosciences
| Metric | ENAV | SGMT |
|---|---|---|
| Market Information | ||
| Market Cap | $0 | $249.31M |
| Market Cap Category | Micro cap | Micro cap |
| 10 Day Avg. Volume | 1,611 | 443,270 |
| 90 Day Avg. Volume | 1,620 | 471,207 |
| Last Close | $34.66 | $7.29 |
| 52 Week Range | $26.31 - $34.70 | $1.73 - $11.41 |
| % from 52W High | -0.12% | -36.11% |
| All-Time High | $34.70 (Sep 23, 2025) | $20.71 (Jan 22, 2024) |
| % from All-Time High | -0.12% | -64.80% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -1.00% | N/A |
| Quarterly Earnings Growth | N/A | N/A |
| Financial Health | ||
| Profit Margin (TTM) | 1.00% | 0.00% |
| Operating Margin (TTM) | N/A | 0.00% |
| Return on Equity (TTM) | 0.07% | -0.38% |
| Debt to Equity (MRQ) | -0.02 | 0.12 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $-4.04 | $4.04 |
| Cash per Share (MRQ) | N/A | $3.86 |
| Operating Cash Flow (TTM) | $-30,403,000 | $-54,230,000 |
| Levered Free Cash Flow (TTM) | $-43,200,000 | $-35,545,376 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | $0.00 | N/A |
Valuation & Enterprise Metrics Analysis: Collaborative vs Sagimet Biosciences
| Metric | ENAV | SGMT |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 14.87 | -5.03 |
| Forward P/E | N/A | -2.05 |
| PEG Ratio | N/A | -0.18 |
| Price to Sales (TTM) | 0.00 | N/A |
| Price to Book (MRQ) | 65.85 | 1.80 |
| Market Capitalization | ||
| Market Capitalization | $0 | $249.31M |
| Enterprise Value | $-76,376,000 | $111.83M |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | -30.55 | N/A |
| Enterprise to EBITDA | 1.77 | -2.05 |
| Risk & Other Metrics | ||
| Beta | N/A | 3.27 |
| Book Value per Share (MRQ) | $-4.04 | $4.04 |
Financial Statements Comparison: Collaborative vs Sagimet Biosciences
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | ENAV | SGMT |
|---|---|---|
| Revenue/Sales | N/A | $0 |
| Cost of Goods Sold | N/A | N/A |
| Gross Profit | N/A | N/A |
| Research & Development | N/A | $15.34M |
| Operating Income (EBIT) | N/A | $-19.87M |
| EBITDA | N/A | $-19.87M |
| Pre-Tax Income | N/A | $-18.18M |
| Income Tax | N/A | N/A |
| Net Income (Profit) | N/A | $-18.18M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | ENAV | SGMT |
|---|---|---|
| Cash & Equivalents | N/A | $64.72M |
| Total Current Assets | N/A | $146.07M |
| Total Current Liabilities | N/A | $7.18M |
| Long-Term Debt | N/A | N/A |
| Total Shareholders Equity | N/A | $138.99M |
| Retained Earnings | N/A | $-313.49M |
| Property, Plant & Equipment | N/A | $38,000 |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | ENAV | SGMT |
|---|---|---|
| Operating Cash Flow | N/A | $-16.70M |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | $-14.54M |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | ENAV | SGMT |
|---|---|---|
| Shares Short | N/A | 3.11M |
| Short Ratio | N/A | 5.61 |
| Short % of Float | N/A | 0.11% |
| Average Daily Volume (10 Day) | 1,611 | 443,270 |
| Average Daily Volume (90 Day) | 1,620 | 471,207 |
| Shares Outstanding | 160.66M | 32.20M |
| Float Shares | N/A | 22.63M |
| % Held by Insiders | N/A | 0.10% |
| % Held by Institutions | N/A | 0.29% |
Dividend Analysis & Yield Comparison: Collaborative vs Sagimet Biosciences
| Metric | ENAV | SGMT |
|---|---|---|
| Last 12-Month Dividend | $0.00 | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | $0.03 | N/A |
| 3-Year Avg Dividend Yield | 0.34% | N/A |
| 3-Year Total Dividends | $0.09 | N/A |
| Ex-Dividend Date | Dec 19, 2023 | N/A |